Table 1.

Baseline characteristics of study participants according to study group

Clinical CharacteristicsAll (n=42)Rilonacept (n=21)Placebo (n=21)P Value
Women, % (n)24 (10)24 (5)24 (5)1.00
Age, yr, mean±SD63±1161±1165±110.29
Race/ethnicity, % (n)1.00
 White non-Hispanic48 (20)48 (10)48 (10)
 Hispanic29 (12)29 (6)29 (6)
 Black23 (10)23 (5)23 (5)
Etiology of CKD, % (n)
 Hypertension52 (22)57 (12)48 (10)0.76
 Type 2 diabetes45 (19)48 (10)43 (9)1.00
 Type 1 diabetes7 (3)5 (1)10 (2)1.00
 ADPKD7 (3)5 (1)10 (2)1.00
 Renal vascular disease14 (3)0 (0)14 (3)0.23
 FSGS5 (1)5 (1)0 (0)1.00
Antihypertensive agent, % (n)100 (42)100 (21)100 (21)1.00
 ACEi/ARB67 (28)52 (11)81 (17)0.10
 Calcium channel blocker50 (25)48 (10)53 (11)1.00
 β Blocker40 (16)38 (8)43 (9)1.00
Statin, % (n)64 (27)52 (11)76 (16)0.18
Smoking status, % (n)0.09
 Never40 (17)43 (9)38 (8)
 Current10 (4)19 (4)0 (0)
 Former50 (21)38 (8)62 (13)
MDRD eGFR, ml/min per 1.73 m2, mean±SD38±1338±1438±120.73
Urine protein-to-creatinine ratio, mg/mmol, median (interquartile range) 0.27 (0.11–0.67)0.34 (0.10–0.61)0.21 (0.11–1.14)0.94
BMI, kg/m2, mean±SD32±532±531±50.49
SBP, mmHg, mean±SD133±17129±26137±190.09
DBP, mmHg, mean±SD79±1079±979±120.65
Serum albumin, g/dl3.88±0.333.88±0.313.89±0.350.73
Baseline hsCRP, mg/L, median (interquartile range)3.8 (1.6–5.9)4.6 (1.9–8.2)3.3 (1.4–5.2)0.14
Baseline IL-6, pg/ml, median (interquartile range)13.5 (7.0–13.50)15.0 (7.0–26.0)9.0 (7.0–25.0)0.60
  • P values are a comparison of rilonacept and placebo groups. ADPKD, autosomal dominant polycystic kidney disease; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; DBP, diastolic BP.